Zymeworks appoints Kristin Stafford as CFO, effective April 1, 2026

Zymeworks Inc.

Stafford previously SVP, CAO at Royalty Pharma; brings life sciences capital markets experience.
Compensation includes $520K annual base salary, 45% target bonus, $52K signing bonus.
Equity awards: 178K options, 119K RSUs (4-year vest), and 50K RSUs (3-year vest).
Kenneth Galbraith ceases as interim CFO but remains CEO and Chairman of the Board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.